



# sensei<sup>TM</sup> BIO

## Sensei Biotherapeutics to Present at Upcoming Conferences

September 4, 2024

BOSTON, Sept. 04, 2024 (GLOBE NEWSWIRE) -- Sensei Biotherapeutics, Inc. (Nasdaq: SNSE), a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients, today announced that Company management will present at the following conferences in September 2024:

### **H.C. Wainwright 26th Annual Global Investment Conference**

Corporate Presentation

Monday, September 9, 2024, at 7:00 a.m. ET.

Virtual and New York, NY

### **2024 Cantor Fitzgerald Global Healthcare Conference**

Fireside Chat

Wednesday, September 18, 2024, at 2:30 p.m. ET.

New York, NY

Webcasts of both presentations will be available on the Investors section of the Sensei website. Replays will be on the website for approximately 90 days following the events.

### **About Sensei Biotherapeutics**

Sensei Biotherapeutics (Nasdaq: SNSE) is a clinical stage immuno-oncology company focused on the discovery and development of next-generation therapeutics for cancer patients. Through its TMAb<sup>TM</sup> (Tumor Microenvironment Activated biologics) platform, Sensei develops conditionally active therapeutics designed to disable immunosuppressive signals or activate immunostimulatory signals selectively in the tumor microenvironment. Sensei's lead investigational candidate is SNS-101, a conditionally active antibody designed to block the V-domain Ig suppressor of T cell activation (VISTA) checkpoint selectively within the low pH tumor microenvironment, where VISTA acts as a suppressor of T cells by binding the receptor PSGL-1. The company is also developing SNS-102, a conditionally active monoclonal antibody targeting V-Set and Immunoglobulin Domain Containing 4 (VSIG-4); SNS-103, a conditionally active monoclonal antibody targeting ecto-nucleoside triphosphate diphosphohydrolase-1 (ENTPDase1), also known as CD39; and SNS-201, a conditionally active VISTAxCD28 bispecific antibody consisting of a CD28 agonist arm and a pH-sensitive anti-VISTA arm. For more information, please visit [www.senseibio.com](http://www.senseibio.com), and follow the company on X @SenseiBio and [LinkedIn](https://www.linkedin.com/company/senseibio).

### **Investor Contact:**

Michael Biega

Senior Director, Investor Relations

Sensei Biotherapeutics

[mbiega@senseibio.com](mailto:mbiega@senseibio.com)

### **Media Contact:**

Joyce Allaire

LifeSci Advisors

[Jallaire@lifesciadvisors.com](mailto:Jallaire@lifesciadvisors.com)